ArticleNature biotechnology2011
First CHO genome.
Article in Nature biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Recombinant erythropoietin expression elevates by ubiquitous chromatin opening element (UCOE) in CHO DG44 cells.Biotechnology letters · 2026Article
- Article
- Membrane Bound E-Cadherin Stimulates PI3K/Akt Signaling.Biology of the cell · 2025Article
- Expression of GNE mutant proteins increases CHO intracellular CMP-Neu5Ac levels without impact on bioprocess performance.Bioprocess and biosystems engineering · 2025Article
- Fc mutagenesis enhances the functionality of anti-RhD monoclonal antibodies.Blood advances · 2025Article
- From Cell Clones to Recombinant Protein Product Heterogeneity in Chinese Hamster Ovary Cell Systems.International journal of molecular sciences · 2025Review
- Optimizing the preparation of labeled N-glycans for rapid, simplified, and high-precision analysis.PloS one · 2025Article
- Driving towards digital biomanufacturing by CHO genome-scale models.Trends in biotechnology · 2024Review
- Identification of a New Integration Site and Study on Site-Specific Integration in CHO-K1 Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Standardized In Vitro Models of Human Adipose Tissue Reveal Metabolic Flexibility in Brown Adipocyte Thermogenesis.Endocrinology · 2023Article
- Article
- Development of a CHO cell line for stable production of recombinant antibodies against human MMP9.BMC biotechnology · 2022Article
- Effects of ubiquitous chromatin opening element (UCOE) on recombinant anti-TNFα antibody production and expression stability in CHO-DG44 cells.Cytotechnology · 2022Article
- Hybrid cell line development system utilizing site-specific integration and methotrexate-mediated gene amplification in Chinese hamster ovary cells.Frontiers in bioengineering and biotechnology · 2022Article
- The high toxicity of DSB-clusters modelling high-LET-DNA damage derives from inhibition of c-NHEJ and promotion of alt-EJ and SSA despite increases in HR.Frontiers in cell and developmental biology · 2022Article
- Compartment-specificEngineering in life sciences · 2021Article
- Advances of Glycometabolism Engineering in Chinese Hamster Ovary Cells.Frontiers in bioengineering and biotechnology · 2021Review
- Validation and identification of reference genes in Chinese hamster ovary cells for Fc-fusion protein production.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- Muscle tissue engineering in fibrous gelatin: implications for meat analogs.NPJ science of food · 2019Article
- The emerging role of systems biology for engineering protein production in CHO cells.Current opinion in biotechnology · 2018Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21822249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.